Source comparison
BPC-157 Help Fibromyalgia Research: Comparison Table
The table below compares BPC-157's documented mechanisms against conventional fibromyalgia treatments and their primary action pathways. BPC-157 Modulates substance P, GABA, serotonin; repairs gut barrier; enhances vagal tone Preclinical evidence of reduced pa
This comparison does not assign a generated winner or score.
- The table below compares BPC-157's documented mechanisms against conventional fibromyalgia treatments and their primary action pathways.
- BPC-157
- Modulates substance P, GABA, serotonin; repairs gut barrier; enhances vagal tone
- Preclinical evidence of reduced pain amplification via BDNF and microglial deactivation
- Direct repair of intestinal tight junctions; documented vagal nerve signaling enhancement
- No human RCTs; extensive animal model data (University of Zagreb studies 2019–2023)
- Mechanistically aligned with fibromyalgia pathophysiology but lacks clinical validation
- Pregabalin (Lyrica)
- Voltage-gated calcium channel blocker (α2δ subunit)
- Reduces excitatory neurotransmitter release in spinal cord
- No direct gut or vagal effects
- FDA-approved; 30–40% of patients achieve ≥50% pain reduction in Phase III trials
- Gold-standard pharmacological option but limited by side effects and partial response
- Duloxetine (Cymbalta)
- SSNRI (serotonin-norepinephrine reuptake inhibitor)
- Enhances descending pain inhibition from brainstem; increases synaptic monoamines
- Indirect effects via serotonin (gut motility) but no barrier repair
- FDA-approved; NNT of 6–8 for ≥30% pain reduction
- Effective for comorbid depression and pain but does not address gut dysfunction
- Low-Dose Naltrexone (LDN)
- Opioid receptor antagonist (transient); upregulates endorphins; modulates microglial activation
- Reduces neuroinflammation via TLR4 pathway inhibition
- Minimal direct gut effects
- Off-label use; small RCTs show 30–45% response rate
- Promising for inflammation modulation; better tolerated than pregabalin
- Gut-Directed Therapy (probiotics, FMT)
- Microbiome restoration; reduced LPS translocation
- Indirect via systemic inflammation reduction
- Direct gut barrier improvement
- Limited fibromyalgia-specific data; IBS comorbidity studies show benefit
- Addresses upstream drivers but slow onset (8–16 weeks)